260 related articles for article (PubMed ID: 17268204)
21. A multicomponent Pseudomonas aeruginosa vaccine consisting of toxoids of protease, elastase, exotoxin A and a common protective antigen (OEP): basic concept of vaccination and prospect of clinical application.
Homma JY; Tanimoto H
Kitasato Arch Exp Med; 1988 Sep; 61(2-3):81-93. PubMed ID: 3145353
[No Abstract] [Full Text] [Related]
22. Active immunization using exotoxin A confers protection against Pseudomonas aeruginosa infection in a mouse burn model.
Manafi A; Kohanteb J; Mehrabani D; Japoni A; Amini M; Naghmachi M; Zaghi AH; Khalili N
BMC Microbiol; 2009 Feb; 9():23. PubMed ID: 19183501
[TBL] [Abstract][Full Text] [Related]
23. A Pseudomonas aeruginosa alginate-exotoxin A conjugate that elicits anti-alginate and exotoxin A-neutralizing antibodies.
Coin D; Vacheron MJ; Guinand M; Michel G
FEMS Microbiol Immunol; 1991 Aug; 3(4):185-92. PubMed ID: 1931130
[TBL] [Abstract][Full Text] [Related]
24. Preclinical laboratory evaluation of a bivalent Staphylococcus aureus saccharide-exotoxin A protein conjugate vaccine.
Ho MM; Bolgiano B; Martino A; Kairo SK; Corbel MJ
Hum Vaccin; 2006; 2(3):89-98. PubMed ID: 17012902
[TBL] [Abstract][Full Text] [Related]
25. Antibody titers in serum of diffuse panbronchiolitis patients administered a multicomponent Pseudomonas aeruginosa vaccine consisting of toxoids of protease, elastase and exotoxin A and a common protective antigen (OEP).
Yamamoto M; Kubota Y; Matsuura M; Homma JY
Kitasato Arch Exp Med; 1988 Sep; 61(2-3):127-35. PubMed ID: 3145352
[No Abstract] [Full Text] [Related]
26. Immunogenicity of synthetic saccharide fragments of Vibrio cholerae O1 (Ogawa and Inaba) bound to Exotoxin A.
Wade TK; Saksena R; Shiloach J; Kovác P; Wade WF
FEMS Immunol Med Microbiol; 2006 Nov; 48(2):237-51. PubMed ID: 17010106
[TBL] [Abstract][Full Text] [Related]
27. Comparative immunochemistry of two fragments from domains Ib and III of Pseudomonas aeruginosa exotoxin A.
Rutault K; Vacheron MJ; Guinand M; Michel G
Infect Immun; 1993 Dec; 61(12):5417-20. PubMed ID: 8225617
[TBL] [Abstract][Full Text] [Related]
28. Recombinant protein composed of Pseudomonas exotoxin A, outer membrane proteins I and F as vaccine against P. aeruginosa infection.
Chen TY; Shang HF; Chen TL; Lin CP; Hui CF; Hwang J
Appl Microbiol Biotechnol; 1999 Oct; 52(4):524-33. PubMed ID: 10570800
[TBL] [Abstract][Full Text] [Related]
29. Use of Pseudomonas aeruginosa toxin A in the construction of conjugate vaccines and immunotoxins.
Cryz SJ; Fürer E; Sadoff JC; Germanier R; Pastan I; Willingham MC; FitzGerald DJ
Rev Infect Dis; 1987; 9 Suppl 5():S644-9. PubMed ID: 3120274
[TBL] [Abstract][Full Text] [Related]
30. Efficacies of alkaline protease, elastase and exotoxin A toxoid vaccines against gut-derived Pseudomonas aeruginosa sepsis in mice.
Matsumoto T; Tateda K; Furuya N; Miyazaki S; Ohno A; Ishii Y; Hirakata Y; Yamaguchi K
J Med Microbiol; 1998 Apr; 47(4):303-8. PubMed ID: 9568995
[TBL] [Abstract][Full Text] [Related]
31. Safety and immunogenicity of Pseudomonas aeruginosa conjugate A vaccine in cystic fibrosis.
Schaad UB; Lang AB; Wedgwood J; Ruedeberg A; Que JU; Fürer E; Cryz SJ
Lancet; 1991 Nov; 338(8777):1236-7. PubMed ID: 1682645
[TBL] [Abstract][Full Text] [Related]
32. An engineered human antibody fab fragment specific for Pseudomonas aeruginosa PcrV antigen has potent antibacterial activity.
Baer M; Sawa T; Flynn P; Luehrsen K; Martinez D; Wiener-Kronish JP; Yarranton G; Bebbington C
Infect Immun; 2009 Mar; 77(3):1083-90. PubMed ID: 19103766
[TBL] [Abstract][Full Text] [Related]
33. Immunization of cystic fibrosis patients with a Pseudomonas aeruginosa O-polysaccharide-toxin A conjugate vaccine.
Cryz SJ; Lang A; Rüdeberg A; Wedgwood J; Que JU; Fürer E; Schaad U
Behring Inst Mitt; 1997 Feb; (98):345-9. PubMed ID: 9382759
[TBL] [Abstract][Full Text] [Related]
34. Reaction of antibody in sera from cystic fibrosis patients with non-toxic forms of Pseudomonas aeruginosa exotoxin A.
Klinger KW; Shuster CW; Klinger J
Eur J Clin Microbiol; 1985 Apr; 4(2):201-6. PubMed ID: 3924609
[TBL] [Abstract][Full Text] [Related]
35. In silico integrative analysis predicts relevant properties of exotoxin-derived peptides for the design of vaccines against Pseudomonas aeruginosa.
Terra ACG; Salvador EA
Infect Genet Evol; 2020 Nov; 85():104424. PubMed ID: 32561294
[TBL] [Abstract][Full Text] [Related]
36. Human single-chain antibodies that neutralize Pseudomonas aeruginosa-exotoxin A-mediated cellular apoptosis.
Santajit S; Seesuay W; Mahasongkram K; Sookrung N; Ampawong S; Reamtong O; Diraphat P; Chaicumpa W; Indrawattana N
Sci Rep; 2019 Oct; 9(1):14928. PubMed ID: 31624289
[TBL] [Abstract][Full Text] [Related]
37. Antigens of Pseudomonas aeruginosa and their use in immunoprophylaxis and immunotherapy.
Stanislavsky ES; Dmitriev BA; Lányi B; Joó I
Acta Microbiol Hung; 1985; 32(1):3-37. PubMed ID: 2412389
[No Abstract] [Full Text] [Related]
38. [The significance of bacterial and host factors in corneal infections caused by Pseudomonas aeruginosa].
Steuhl KP; Döring G; Thiel HJ
Fortschr Ophthalmol; 1989; 86(4):283-6. PubMed ID: 2507425
[TBL] [Abstract][Full Text] [Related]
39. [Protective polysaccharide-protein artificial antigens from O-specific polysaccharides of Pseudomonas aeruginosa and its exotoxin A].
Dmitriev BA; Kul'shin VA; Antsiferova NG; Vovk VA; Moroz AF
Dokl Akad Nauk SSSR; 1988; 298(5):1277-80. PubMed ID: 2454182
[No Abstract] [Full Text] [Related]
40. Synthesis and characterization of a Pseudomonas aeruginosa alginate-toxin A conjugate vaccine.
Cryz SJ; Fürer E; Que JU
Infect Immun; 1991 Jan; 59(1):45-50. PubMed ID: 1898901
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
